Stocks · News reference
Sionna Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Sionna Therapeutics reported its financial results for the third quarter ended September 30, 2026, and disclosed a significant workforce reduction implemented in September.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Sionna Therapeutics announced it will advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in Q1 2027. The company reported a strong cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029. However, the company implemented a 46% workforce reduction in September 2026 to focus resources on the dual combination program and extend its operating runway.
8-K filing — Sionna Therapeutics, Inc. (SION)
Filed: 2026-11-10 AccNo: 0001628280-26-072497 Size: 229 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Sionna Therapeutics, Inc. Schedules Q3 2026 Earnings Announcement
Sionna Therapeutics, Inc. has scheduled the release of its third-quarter 2026 financial results for November 11, 2026.
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
Sionna Therapeutics, Inc. announced that its management team will participate in fireside chats at two upcoming healthcare investor conferences in November 2026.
Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6
Wedbush analyst Laura Chico maintains Sionna Therapeutics (NASDAQ:SION) with a Neutral and raises the price target from $5 to $6.